tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Alopecia D000505 14 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Stomatitis D013280 14 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Corneal Diseases D003316 13 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Glucose Intolerance D018149 13 associated lipids
Bradycardia D001919 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Rosacea D012393 13 associated lipids
Hematuria D006417 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Critical Illness D016638 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypoglycemia D007003 13 associated lipids
Urticaria D014581 13 associated lipids
Biliary Fistula D001658 13 associated lipids
Osteoporosis D010024 12 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Listeriosis D008088 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Eye Diseases D005128 12 associated lipids
Crohn Disease D003424 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Keloid D007627 12 associated lipids
Hypertension, Portal D006975 12 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Retinoblastoma D012175 12 associated lipids
Shock D012769 11 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Thinness D013851 11 associated lipids
Shock, Septic D012772 11 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Dehydration D003681 11 associated lipids
Exanthema D005076 11 associated lipids
Hyperpigmentation D017495 11 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Influenza, Human D007251 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Dumont FJ et al. A tacrolimus-related immunosuppressant with reduced toxicity. 1998 Transplantation pmid:9448138
Schwartz JJ et al. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. 2007 Transplantation pmid:17893604
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Levy G et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. 2004 Transplantation pmid:15201658
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Andrades KM et al. Modulation of Candida albicans virulence by antirejection immunosuppressant drugs. 2013 Transplantation pmid:23380869
Tydén G et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. 2007 Transplantation pmid:17496528
Faguer S et al. Rituximab therapy for acute humoral rejection after kidney transplantation. 2007 Transplantation pmid:17496547
Rodrigo E et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. 2016 Transplantation pmid:26703349
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Furukawa H et al. The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. 1992 Transplantation pmid:1373531
Sakr M et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. 1992 Transplantation pmid:1373535
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Pescovitz MD et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. 2009 Transplantation pmid:19855247
Miroux C et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. 2012 Transplantation pmid:22743548
Stegall MD et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. 1997 Transplantation pmid:9422404
Shield CF et al. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9422413
David-Neto E et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. 2007 Transplantation pmid:17627237
Larsen JL et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. 2006 Transplantation pmid:16926589
Xue F et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. 2010 Transplantation pmid:20010326
Welberry Smith MP et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. 2013 Transplantation pmid:24056618
Ciancio G et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. 2002 Transplantation pmid:11965039
Petruzzo P et al. The International Registry on Hand and Composite Tissue Transplantation. 2010 Transplantation pmid:21052038
de Graav GN et al. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. 2017 Transplantation pmid:28403127
Watanabe M et al. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. 2013 Transplantation pmid:23860082
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Lenaers JI et al. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. 2006 Transplantation pmid:17102764
Nogueira JM et al. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. 1999 Transplantation pmid:10096529
Atkison PR et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. 1997 Transplantation pmid:9311719
van Rijen MM et al. CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. 2002 Transplantation pmid:12042657
Yamamoto S et al. FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. 2004 Transplantation pmid:15591950
Tan HP et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. 2004 Transplantation pmid:15591960
Higgins RM et al. Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. 2004 Transplantation pmid:14966430
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Mahé E et al. Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. 2004 Transplantation pmid:14966435
Paramesh AS et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. 2004 Transplantation pmid:14724447
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Vivarelli M et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 2010 Transplantation pmid:20098287
Gallon L et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. 2006 Transplantation pmid:16477235
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Boillot O et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. 1998 Transplantation pmid:9825815
Sanchez EQ et al. Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. 2010 Transplantation pmid:20098288
Moreau C et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. 2006 Transplantation pmid:16477241
Jain AB et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. 1998 Transplantation pmid:9825817
Niioka T et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. 2012 Transplantation pmid:23073468
Guerville F et al. Transplantation with pathologic kidneys to improve the pool of donors: an example of shunt nephritis. 2012 Transplantation pmid:22487813
Mathis AS et al. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. 2001 Transplantation pmid:11374405
Swinnen LJ et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. 2008 Transplantation pmid:18645482
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Fujii Y et al. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. 1989 Transplantation pmid:2472025
Welberry Smith MP and Baker RJ The author's reply. 2014 Transplantation pmid:24978039
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Pascual M et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. 1998 Transplantation pmid:9869086
Srinivas TR et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. 2005 Transplantation pmid:16251854
Buell JF et al. Malignancy after transplantation. 2005 Transplantation pmid:16251858
Hariharan S Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). 2002 Transplantation pmid:12357988
Zaltzman JS A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. 2010 Transplantation pmid:21166111
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Fisher A et al. FK506 hepatotoxicity in liver allograft recipients. 1995 Transplantation pmid:7539961
Oike F et al. A 12-day course of FK506 allows long-term acceptance of semi-identical liver allograft in inbred miniature swine. 2000 Transplantation pmid:10868630
Gloor JM et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. 2002 Transplantation pmid:12131699
Aw MM et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. 2003 Transplantation pmid:12660504
Charpentier B et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. 2003 Transplantation pmid:12660513
Anil Kumar MS et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. 2005 Transplantation pmid:16210969
Jain A et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. 2005 Transplantation pmid:16210976
van Boekel GA et al. Effect of mild diarrhea on tacrolimus exposure. 2012 Transplantation pmid:22955188
Ellis D et al. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. 2007 Transplantation pmid:17589338
Webb NJ et al. Corticosteroid-free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. 2015 Transplantation pmid:25539467
Yoo MC et al. Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. 2015 Transplantation pmid:25539464
Lake JR et al. The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. 1995 Transplantation pmid:7482713
Kainz A et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. 2000 Transplantation pmid:11152103
Mathew A et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. 1995 Transplantation pmid:7482730
MacDonald AS Impact of immunosuppressive therapy on hypertension. 2000 Transplantation pmid:11152235
Brito-Costa A et al. Factors Associated With Changes in Body Composition Shortly After Orthotopic Liver Transplantation: The Potential Influence of Immunosuppressive Agents. 2016 Transplantation pmid:27136260
Stephen M et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. 1989 Transplantation pmid:2463701
Gruessner RW et al. Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. 2004 Transplantation pmid:15239611
Gralla J and Wiseman AC The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. 2010 Transplantation pmid:20595929
Tsamandas AC et al. Central venulitis in the allograft liver: a clinicopathologic study. 1997 Transplantation pmid:9256183
Glotz D et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. 2010 Transplantation pmid:20386144
Sher LS et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. 1997 Transplantation pmid:9256184
Tricot L et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. 2005 Transplantation pmid:16371923
Yuzawa K and Fukao K Topical FK506 ointment for skin grafting. 1998 Transplantation pmid:9565111
Margreiter R et al. A double-hand transplant can be worth the effort! 2002 Transplantation pmid:12134104
Opelz G and Döhler B Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. 2011 Transplantation pmid:21452411
Veenhof H et al. Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. 2017 Transplantation pmid:27906832
Jin L et al. Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats. 2018 Transplantation pmid:29319618
Miura Y et al. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. 2011 Transplantation pmid:21452412
MacPhee IA and Holt DW A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. 2008 Transplantation pmid:18212618
Cezário ES et al. Gingival overgrowth in renal transplant subjects medicated with tacrolimus in the absence of calcium channel blockers. 2008 Transplantation pmid:18212628
Rayar M et al. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. 2018 Transplantation pmid:29315140
Gillard P et al. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. 2008 Transplantation pmid:18212631
Tourret J et al. Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. 2017 Transplantation pmid:27681266
Kuypers DR et al. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. 2006 Transplantation pmid:16794545